Seoul National University medical professors Mook In-hee and Lee Dong-yeong said on October 23 that their research team developed a blood test-based Alzheimer’s disease prediction technique and transferred the technique with a prediction accuracy of about 90% to Medifron DBT. 130 million won was paid in advance for the technology transfer and the running royalty is equivalent to 3% of net sales.
At present, Alzheimer's disease and dementia treatment can be conducted only after symptoms are shown although it is extremely critical to slow down the progress based on diagnosis preceding brain cell damage. The research team focused on the fact that the brains of Alzheimer's disease and dementia patients carry the beta-amyloid protein in quantity even before symptoms are shown and the disease can be predicted based on it.
To be specific, the team developed three different techniques. One is related to blood sample pretreatment for preventing enzymes in blood from degrading the beta-amyloid protein in the brains of the patients. The rest are four proteins and four blood factors that can help detect amyloid deposition in the brains.
Professor Mook In-hee said that the technique developed by the team distinguishes itself from the existing ones in that it allows the disease to be predicted even without the detection of symptoms. Details of the research are available in the March edition of the Alzheimer’s Research & Therapy journal.